ClinicalTrials.gg
RecruitingNCT07672756Updated Jul 1, 2026

A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)

A Phase 1 interventional study of PL54 in Phenylketonuria (PKU), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jul 2025, registered Jun 2026).
  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this clinical trial is to evaluate the safety and tolerability of single and multiple administrations of PL54 in patients aged 18-55 years. The key questions it aims to answer include:

How safe and tolerable is PL54 in PKU patients following single and multiple administrations?

Researchers will compare the safety and tolerability profiles between single and multiple dosing regimens to assess PL54.

Participants will be required to:

Phase Ia (Single Administration):

Receive a single subcutaneous injection of PL54 based on body weight. Undergo a 28-day observation period post-injection. Visit the clinic for assessments on: D1 (administration day), D2, D7, D8, D10, D15, D22, and D29.

Phase Ib (Multiple Administrations):

Receive subcutaneous injections of PL54 every 7 days (4 doses total) based on body weight. Undergo a 35-day observation period after the last injection. Visit the clinic for assessments on: D1 (first administration), D3, D8, D15, D21, D22, D29, D36, D43, and D57

Data to be recorded include:

Incidence, severity, seriousness, relationship to PL54 treatment, duration, and outcome of adverse events (AEs).

Change from baseline in blood phenylalanine (Phe) concentration.

Read the detailed description

This is a multicenter, open-label, dose-escalation Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single or multiple subcutaneous injections of PL54 injection in adult patients with phenylketonuria (PKU). The trial is divided into Phase Ia and Phase Ib.

Phase Ia:

A single subcutaneous injection will be administered. The phase includes a 2-week screening period, a single administration on Day 1 (D1), and a 4-week follow-up period, totaling approximately 6 weeks. Approximately 30 subjects will be enrolled across five dose groups: 0.01 mg/kg, 0.04 mg/kg, 0.1 mg/kg, 0.25 mg/kg, and 0.5 mg/kg, with 6 subjects per group (including 1 sentinel). The first subject in each dose group will receive a single subcutaneous injection of PL54, and the remaining subjects in the same dose group will be enrolled only after the first subject has completed at least 14 days of safety assessment. Dose escalation to the next group will proceed only after all subjects in the previous dose group have completed at least 14 days of visit assessments and the Safety Monitoring Committee (SMC) determines that the dose escalation termination criteria have not been met.

Phase Ib:

Approximately 18 subjects will be enrolled. Subcutaneous injections will be administered once weekly for 4 consecutive weeks (the dosing period for subsequent dose groups may be adjusted based on observed anti-drug antibody [ADA], pharmacokinetic [PK], and pharmacodynamic [PD] results from previous dose groups). Three dose groups are planned: 0.04 mg/kg, 0.1 mg/kg, and 0.25 mg/kg, with 6 subjects per group (the actual dose groups and dosing regimen will be adjusted based on Phase Ia results). Dose escalation to the next group will proceed only after all subjects in the previous dose group have completed at least 28 days of visit assessments and the SMC determines that the dose escalation termination criteria have not been met.

02

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

Keywords

  • Phenylketonuria
  • PKU
03

In context

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

This study's planned enrollment of 48 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.

Browse Phenylketonurias studies →

Lead sponsor

Chongqing Peg-Bio Biopharm Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adult patients aged 18 to 55 years, inclusive, regardless of sex.
  • Subjects with a prior diagnosis of phenylketonuria (PKU) meeting the following criteria:

    • Blood Phe concentration ≥600 µmol/L at screening;
    • Average blood Phe concentration ≥600 μmol/L within the 12 months prior to screening (with at least two test results available);
    • Genetic test report confirming the presence of phenylalanine hydroxylase (PAH) gene defects.
  • Ability to maintain dietary stability from 3 days prior to screening through the end of the trial.
  • Subjects (including partners) capable of practicing effective during the trial period, with no plans for conception within 3 months after trial completion.
  • Voluntarily sign the form and, in the investigator's judgment, able to comply with all study requirements.

Key Exclusion Criteria:

  • Known to PL54 injection or any of its .
  • Medical conditions or history assessed by the investigator that may increase the risk of severe allergic reactions (e.g., acute exacerbation of allergic asthma, atopic constitution, history of anaphylaxis, etc.).
  • Use of any medication for PKU (including large neutral amino acids) within 14 days prior to study drug administration or within 5 half-lives of the drug (whichever is longer).
  • Use or planned use of any injectable medication containing polyethylene glycol (PEG) (except the drug) within 3 months prior to screening or during the study period, including medroxyprogesterone acetate injection.
  • Prior use of Pegvaliase (PALYNZIQ®).
  • History of any of the following manifestations associated with prior PEG-containing product use: systemic symptoms (e.g., respiratory or gastrointestinal symptoms, hypotension, angioedema, allergic reactions). The investigator will determine eligibility based on the severity of previous symptoms.
  • abnormal vital signs, physical examination, laboratory tests, or other relevant findings at screening, deemed by the investigator to render the subject unsuitable for enrollment.
  • Significant medical history of immunological, cardiovascular, respiratory, gastrointestinal, endocrine, renal, hematological, neurological, psychiatric, or malignant diseases (except basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been excised with no evidence of recurrence) assessed by the investigator prior to screening.
  • Stable use of (e.g., cyclosporine, azathioprine) within 4 weeks prior to screening, with inability to discontinue use during the study period.
  • Vaccination within 4 weeks prior to screening or planned vaccination during the study period.
  • Positive serology for Treponema pallidum-specific antibodies, (HIV) antibodies, virus (HCV) antibodies, or virus (HBV) surface antigen.
  • Serum creatinine ratio > 1.5 × (ULN).
  • (ALT) > 2 × ULN.
  • Pregnant or breastfeeding women.
  • Participation in any investigational drug trial and receipt of an investigational product within 3 months prior to screening.
  • Prior use of any gene therapy for phenylketonuria (including participation in clinical studies).
  • Any other condition deemed by the investigator to preclude participation in the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    PL54

    subcutaneous injection administration. Single -dose escalation will start from the initial dose of 0.01 mg/kg and proceed sequentially to higher doses.

    Biological: PL54

Interventions

  • BiologicalPL54

    Phase Ia: Single, subcutaneous injection administration. Dose escalation will start from the initial dose of 0.01 mg/kg and proceed sequentially to higher doses. Phase Ib: Administration via subcutaneous injection. Dosing frequency: once weekly. Dose escalation will start from the initial dose of 0.04 mg/kg and proceed sequentially to higher doses.

    Also known as: PEGylated Recombinant Phenylalanine Ammonia-Lyase

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    including the incidence of overall and categorized AEs

    Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib

Secondary outcomes

  1. The change in blood phenylalanine concentration from baseline

    Comparing the average phenylalanine concentrations at different timepoints and different doses with the concentration at baseline in Phase Ia and Phase Ib studies.

    Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib

  2. The proportion of subjects whose blood phenylalanine concentration decreased to the target range (60-600 μmol/L)

    Monitor the blood phenylalanine concentration at each visit and calculate the proportion of subjects whose phenylalanine concentration drops to the target range (60-600 μ mol/L) for each dose group in Phase Ia and Phase Ib studies.

    Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib

  3. PK parameters of PL54 after single dose and multiple doses

    Calculate the following PK parameters, including but not limited to Cmax, Tmax, AUC0-t, AUC0-∞, T1/2, λz, CL/F, Vz/F for Phase Ia, and AUC0-τ, Cmin,ss, Cmax,ss, Tmax,ss, T1/2 for Phase Ib.

    Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib

  4. Immunogenicity of PL54

    Total anti-drug antibodies (if applicable), anti-PAL4 antibodies, anti-PEG IgG/IgM, neutralizing antibodies that inhibit PL54 activity (NAbs), and detection of anti-PL54 IgE antibodies in subjects experiencing severe allergic reactions (WAO criteria).

    Time frame: Day 1-29 of Phase Ia; Day 1-57 of Phase Ib

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    Recruiting
    • Huan Zhou · Contactsunj@pegbiocq.com · 86-13983367811
    • Jianping Weng · Principal investigator
    • Huan Zhou · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 29, 2026
StartActual
Jul 20, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07672756
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jul 20, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Jing Sun
Contact
sunj@pegbiocq.com
86-13983367811

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion